Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)

NCT01500551 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01500551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01500551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Completed
Start date
March 18, 2013
Completion date
February 12, 2025
Enrollment
302 (actual)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile idiopathic arthritis